title: Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine.
abstract: Patients with Parkinson's disease (PD) can experience cognitive impairment. There are currently no medications indicated for the treatment of cognitive impairment in PD. Clinicians are faced with the dilemma as to whether or not to treat patients with PD with the acetylcholinesterase inhibitors that are currently approved for use in Alzheimer's disease (AD) and that have shown promise in clinical trials of Dementia with Lewy bodies (DLB). Although these medications may help cognition, there is a theoretical concern that by increasing acetylcholine relative to dopamine, they might worsen motor function. We report the case of a patient with PD and cognitive impairment who developed a marked worsening of motor function, mood, and anxiety in the setting of a pharmacologic challenge study using a 3-mg oral dose of the acetylcholinesterase inhibitor, rivastigmine. We believe that the mechanism of the motor and perhaps psychiatric worsening was increased central cholinergic tone. We conclude that further studies should be done to evaluate the efficacy and tolerability of these agents in this illness but that caution should be exercised when using acetylcholinesterase inhibitors in patients with PD.
authors.affiliation: Department of Neurology, University of Rochester School of Medicine and Dentistry, New York 14642, USA. irichard@mct.rochester.edu
authors.forename: Irene Hegeman
authors.initials: IH
authors.lastname: Richard
authors.forename: Anne Wallace
authors.initials: AW
authors.lastname: Justus
authors.forename: Nigel H
authors.initials: NH
authors.lastname: Greig
authors.forename: Frederick
authors.initials: F
authors.lastname: Marshall
authors.forename: Roger
authors.initials: R
authors.lastname: Kurlan
mesh_terms: D000284:Administration, Oral; D000339:Affect / Q000187:drug effects*; D000368:Aged; D001007:Anxiety; D002219:Carbamates / Q000009:adverse effects* / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009043:Motor Activity / Q000187:drug effects*; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*; D048448:Phenylcarbamates; D000068836:Rivastigmine; D013997:Time Factors
chemical_list: D002219:Carbamates; D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine